Paclitaxel Repackaged in an Albumin-Stabilized Nanoparticle: Handy or Just a Dandy?
Authors:
- 1 November 2005
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (31) , 7765-7767
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- Peripheral neuropathy: A persisting challenge in paclitaxel-based regimesEuropean Journal of Cancer, 2006
- Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast CancerJournal of Clinical Oncology, 2005
- Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 WeeksJournal of Clinical Oncology, 2005
- Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxelCancer Biology & Therapy, 2005
- MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecidInternational Journal of Cancer, 2005
- Association of Paclitaxel Pharmacokinetics with the Development of Peripheral Neuropathy in Patients with Advanced CancerClinical Cancer Research, 2005
- Docetaxel administration schedule: From fever to tears? A review of randomised studiesEuropean Journal of Cancer, 2005
- Analysis of the Drug Resistance Profile of Multidrug Resistance Protein 7 (ABCC10)Cancer Research, 2004
- Taxane-Mediated Antiangiogenesis in Vitro Cancer Research, 2004
- Pharmacological Effects of Formulation VehiclesClinical Pharmacokinetics, 2003